investor daily logo

ClearView hires from within

By Jessica Penny
2 minute read

The firm has selected one of its alternative directors to assume the role of a non-executive director.

ClearView has announced the appointment of Eloise Watson as non-executive director who will be stepping down from her current role as alternative director for Nathaniel Thomson.

Watson, who is a partner of private equity firm Crescent Capital Partners, has worked with a range of businesses across the healthcare, industrial, and consumer retail sectors.

Before joining Crescent, Watson served in venture capital investing in early-stage, Australian-based start-ups.

She also assumes her new role with experience in investment banking from Goldman Sachs and is currently a director of Healthcare Australia.

ClearView non-executive chairman Geoff Black commented: “Eloise Watson brings extensive expertise in healthcare and investment to the ClearView board and an understanding of ClearView, having served as alternate director for Nathaniel Thomson.”

“I look forward to Eloise’s ongoing contribution to the ClearView board in her new capacity as non-executive director.”

The financial services group also announced that Michael Alscher will retire as a non-executive director and be appointed as an alternate director for Watson.

In February, ClearView reported that its underlying net profit after tax for the six months to 31 December increased 37 per cent on the previous corresponding period to $17.3 million.

Managing director Nadine Gooderick said the group’s focus on simplification and ongoing investment in technology and transformation over the past few years had seen it exit unprofitable segments and give the business a clear strategy and clear targets for FY2026.

“We are solely focused on delivering high-quality life insurance solutions and excellent service to our customers. We have invested significantly in people, processes and technology, and this investment underpins our long-term growth profile,” Gooderick said at the time.

Looking forward, ClearView expects the business to emerge as a life insurance business that is focused on protecting and optimising its position as a dynamic challenger. The firm is targeting a market share of new business of 12–14 per cent by financial year 2026.